<DOC>
	<DOCNO>NCT01854294</DOCNO>
	<brief_summary>GM604 endogenous human embryonic stage neural regulatory signal peptide control development , monitor correction human nervous system . Neurological disease multisystem , multifactorial , single target drug ineffective . Genervon 's Master Regulators play significant role embryonic/fetal nervous system development potent disease modification drug candidate modulate many pathway include inflammation , apoptotic , hypoxia ... The study drug regulatory peptide sequence identical one active site human Motoneuronotrophic Factor manufacture solid phase synthesis . Pre-clinical research indicate neuro-protective agent animal model ALS , motorneuron disease , PD , neuro-degenerative disease stroke . GM604 control modulates many know significant ALS gene positive effect interactively dynamically multiple pathway , twenty-two biological process , include neuro-protection , neurogenesis , neural development , neuronal signaling , neural transport , process . GM6 cocktail drug , one master regulator peptide drug function multiple pathway . Genervon hypothesize study biomarkers protein expression ALS gene SOD1 protein expression substance tau , NF-H , Cystatin C indication degeneration neuron CSF collect ALS patient provide information possible GM604 's mechanisms action treat ALS . 1 . This pilot trial design test proof principle , i.e . determine 2-week IV bolus treatment agent ( 1 ) change ALS protein expression ( target biomarkers efficacy biomarkers ) treatment ( 2 ) preliminary effect measure ALS disease clinical progression . Study Objectives : 1 . To test safety tolerability GM604 population ALS patient . 2 . To test change ALS biomarkers treatment . 3 . To determine preliminary effect injection GM604 measure ALS disease biomarkers clinical progression</brief_summary>
	<brief_title>GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial Amyotrophic Lateral Disease ( ALS )</brief_title>
	<detailed_description>Background 1 . In early 1990s Genervon hypothesize CNS/PNS rare motoneuron diseases disorder involve interplay highly complex , multifactorial process many non-dominant effector interactive dynamic network . Therefore Genervon decide drug development strategy classic single target drug development paradigm likely leading cure . 2 . Genervon also hypothesize age likely initial multifactorial trigger lead multiple defective degrade gene product accumulate advance year . However key cure many human neurological disorder subsequent common terminal cascade coincide onset neurological deficit . The terminal cascade involves share pathway interactive multifactorial pathogenic mechanism lead ultimate demise neuron . Therefore Genervon 's strategy find trigger residue debris neuron death discrete area central nervous system . 3 . Genervon recognize limited human capacity design drug dynamically interactively modulate multiple pathway gene . Therefore one possible drug development strategy find endogenous early stage regulatory molecule ( ) control development , monitor correction human nervous system . 4 . Genervon develop novel proprietary technology platform name Protein Bands Selection Function find fetal signal regulator . One discoveries 33 amino acid peptide name human Motoneuronotrophic Factor ( MNTF ) , gene sequence chromosome location . 5 . Genervon develop another novel platform name In Silico Analysis find active site within big protein . Within MNTF peptide , Genervon identify family nine embryonic stage human multifactorial master regulator govern nervous system development , protection correction . These master regulator highly express week 9 embryonic/fetal development , time incredible intricacy , truly remarkable consistency well . 6 . Genervon develop one nine master regulator name GM6 disease modification CNS/PNS neurodegenerative disease disorder share common pathway interactive multifactorial pathogenic mechanism . GM6 bind Insulin Receptor beta sub-unit IGF1R/IGF2R also identical sub-unit . GM6 penetrate Blood Brain Barrier ( BBB ) activate many appropriate gene multiple pathway induce anti-inflammatory , anti-apoptotic , anti-oxidative regenerative effect response dynamic distress signal nervous system . 7 . GM6 also know GM604 , GM602 GM608 . Drug name GM604 assign ALS indication . GM602 assign stroke indication . GM608 assign Parkinson Disease indication . 8 . The investigational drug GM604 regulatory/signaling peptide sequence identical one nine active site human Motoneuronotrophic factor ( MNTF ) , also refer GM6 study . MNTF novel human endogenous developmental stage neurotrophin nervous system specific human chromosome location . 9 . Pre-clinical efficacy study : The investigator ' preclinical animal study show intravenously inject GM604 able penetrate blood-brain barrier enter brain . GM604 show neuroprotection variety vitro animal model numerous CNS disease include ALS , ischemic stroke , spinal cord injury , Parkinson 's disease ( PD ) , MS , Alzheimer Huntington Disease . 10 . GM6 provide neuroprotection neuron vitro soluble inflammatory factor human CSF patient various CNS disease . It increase neuron survival 175 % exposure ALS patient ' CSF , 191 % AD patient ' CSF , 198 % PD patient ' CSF , 205 % Stroke patient ' CSF , 246 % MS patient ' CSF 273 % HD patient ' CSF . 11 . Preclinical research animal model indicate GM604 neuroprotective agent animal model ALS , motoneuron disease , Parkinson 's disease stroke . In ALS model , SOD1 mouse Jackson Lab stock # G93A treat GM604 0 , 1 5 mg/kg . SOD1 mouse examine age disease onset , age death , behavioral expression disease ( CS=Clinical score ) . GM604 prolong life span ALS mouse SOD1 30 % [ ( 163.5-126 ) /126 = 30 % ] , delay median clinical score 53 % , delay symptom onset 27 % [ ( 145.5-114.5 ) /114.5 = 27 % ] 5 mg/kg dose . The conclusion GM6 significantly show dose dependent effect delay age onset disease , age death , increase grip strength rota-rod performance , improve clinical score treat animal . 12 . The investigator find later study Wobbler Mouse model optimal dose SOD1 mouse model probably 20 mg/kg probably see even significant effect 20 mg/kg use SOD1 mouse study . 13 . GM604 20mg/kg dramatically increase survival life span 500 % ( 6 fold 7-14 week 55-65 week ) control animal animal treat low dos GM6 show continual decrease grip strength . Wobbler mouse treat GM6 10-20 mg/kg show improvement grip strength 4 week ( 3 fold ) . GM604 10 20 mg/kg treatment show significant increase body weight 8 week follow treatment.GM604 10 20 mg/kg treatment increase preservation motor neuron 160 % ( 2.6 fold ) . The conclusion GM604 find efficacious vivo mouse model neurological disease . The effectiveness GM604 dose-dependent indicate GM604 may beneficial treat various neurological disorder . Rationales 1 . This pilot trial design test proof principle , i.e . determine 2-week IV bolus treatment agent ( 1 ) change ALS protein expression ( target biomarkers efficacy biomarkers ) treatment ( 2 ) preliminary effect measure ALS disease clinical progression . 2 . Previous human experience : A Phase 1 Clinical Trial Study complete . The Phase 1 Trial primary objective determine safety tolerability establish pharmacokinetic pharmacodynamic property GM602 0.5 , 1.5 , 5.0 mg/kg administer single bolus intravenous dose human subject 3 consecutive daily dos GM602 high safe tolerate dose 5.0 mg/kg . The Phase 1 study establish 3 consecutive daily dose 5.0 mg/kg GM602 safe tolerate . 3 . Concurrently , IND on-going clinical trial GM6 : IND 77,789 : `` A Phase 2 double blind , randomize , placebo control dose escalation Study Evaluate Efficacy Safety GM602 Patients Acute Middle Cerebral Artery Ischemic Stroke within 18 h-hour treatment window . Acronym/Title GMAIS . GM602 receive fast track designation ischemic stroke 2007 . The stroke trial complete enrollment unblinded treatment randomization generate drug relate safety report . IND 109,441 : `` GM602 A Phase IIA Pilot double-blinded , randomize , placebo control trial mild moderate Parkinson Disease ( PD ) . Acronym/Title GAP-PD . The PD trial recruiting patient . Possible GM604 MOA ALS 1 . More scientist publish paper advocate ALS multifactorial disease . Other rare disease include CNS/PNS diseases disorder multifactorial multisystem disease well , i.e . multiple interactive biologic system gene compromise fail like domino . 2 . One major reason CNS clinical trial uniformly fail classic drug development paradigm design single target drug CNS/PNS rare disease ' pathogenesis simply would able handle multifactorial nature complex disease . 3 . An initial trigger ( ) likely multifactorial cumulative follow terminal cascade also involve interactive multifactorial pathogenic mechanism , coincide onset neurological deficit , gene mutation expression misfolded protein . That simply single target drug able job . Most neurological disease disorder common underlie pathogenic mechanism lead neural death . Our drug development strategy find endogenous regulator interactively dynamically modulate common underlie pathogenic mechanism . 4 . Genervon change drug development paradigm hit single gene/pathway comprehensive dynamic , multifactorial approach treat complex rare neurodegenerative disease multi-factorial drug GM604 . GM604 one embryonic/fetal stage MNTF master regulator endogenous signal peptide development regulation nervous system development . GM604 multifactorial corrects inadvertent error embryonic/fetal development neuroprotection correction property may apply neurodegenerative disease therapy adult . 5 . Genervon study mechanisms action GM6 DNA microarray technique . GM604 control modulates many know significant ALS gene positive effect , multiple pathway interactively , systemically dynamically . Our master regulator peptide drug modulate one many ALS relate gene . It cocktail drug , one master regulator peptide drug . 6 . Mechanisms postulate ALS complex interplay multiple pathogenic process include oxidative stress , protein aggregation , mitochondrial dysfunction excitotoxicity , impair axonal transport . GM604 modulate gene involve pathway others . Genervon also identify gene test target . 7 . ALS notoriously fatal many alternate form different pathogenesis . Therefore previous single target drug trial restrict enrollment small selective segment ALS patient . With potential GM604 function multiple pathway modulate multiple ALS relate gene , Genervon believe GM604 potentially treat ALS patient variety segment instead restrict small selective segment ALS patient . Genervon propose ALS Phase 2 clinical trial broadly inclusive . Use Biomarkers ALS Most late-phase clinical trial across disease fail demonstrate drug efficacy case control . The incorporation biomarkers within clinical trial may reduce 'drug attrition ' rate . The biomarkers incorporate clinical trial subdivide : 1 . 'Target ' biomarkers ( drug hit target , therefore , provide benefit ) , 2 . 'Efficacy ' biomarkers ( indicator positive drug effect ( result ) via mechanism drug action ) . 3 . 'Efficacy/Target biomarkers . Genervon hypothesize modulate disease cause gene may modulate ALS disease progression .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Patients ALS : Familial Sporadic ALS , symptom onset &lt; equal 24 month . 2 . At least 18 year age 3 . Subjects meet El Escorial criterion definite criterion diagnosis ALS . 4 . Subjects stable dose riluzole least month take initiating riluzole duration trial . 5 . Not experimental medication last 1 month five time halflife experimental medication . 6 . At screening , must Forced Vital Capacity ( FVC ) â‰¥ 65 % predict capacity age , height gender . 7 . Have fully complete informed consent form 8 . Ability comply study procedures 9 . Women childbearing age must birth control . Pregnancy test do woman child bear age . 10 . Medically safe lumbar puncture collect CSF 1 . History liver disease , severe renal failure , diabetes , coronary heart disease , cancer 2 . Clinically significant EKG abnormality screen 3 . Any comorbid condition would make completion trial unlikely 4 . FVC &lt; 65 % 5 . Presence bleed disorder 6 . Allergy local anesthetic 7 . Problem CSF pressure 8 . Topical skin infection lumbar puncture site 9 . BMI &gt; 32 kg/m2 10 . Medical surgical condition lumbar puncture contraindicate 11 . Use antiplatelet anticoagulant drug , plavix , aggrenox , ticlid , warfarin coumadin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>motorneuron disease</keyword>
	<keyword>Central Nervous System ( CNS ) disease</keyword>
	<keyword>neurodegeneration</keyword>
	<keyword>neuroprotective</keyword>
	<keyword>mechanism action</keyword>
	<keyword>pathway</keyword>
	<keyword>biomarkers</keyword>
	<keyword>Cerebral Spinal Fluid ( CSF )</keyword>
	<keyword>blood biomarkers</keyword>
	<keyword>multi-factorial</keyword>
	<keyword>multisystem</keyword>
	<keyword>single target</keyword>
	<keyword>pathogenic mechanism</keyword>
	<keyword>Protein Bands Selection Function</keyword>
	<keyword>silico analysis</keyword>
	<keyword>active site</keyword>
	<keyword>protein</keyword>
	<keyword>peptide</keyword>
	<keyword>embryonic stage</keyword>
	<keyword>endogenous</keyword>
	<keyword>master regulator</keyword>
	<keyword>fetal development</keyword>
	<keyword>embryonic development</keyword>
	<keyword>common pathway</keyword>
	<keyword>Blood Brain Barrier ( BBB )</keyword>
	<keyword>anti-inflammatory</keyword>
	<keyword>anti-apoptotic</keyword>
	<keyword>anti-oxidative</keyword>
	<keyword>regenerative</keyword>
	<keyword>distress signal</keyword>
	<keyword>neurotrophin</keyword>
	<keyword>Motoneuronotrophic factor ( MNTF )</keyword>
	<keyword>ALS model</keyword>
	<keyword>life span</keyword>
	<keyword>disease onset</keyword>
	<keyword>grip strength</keyword>
	<keyword>protein expression</keyword>
	<keyword>DNA microarray</keyword>
	<keyword>differential expression</keyword>
	<keyword>Phase 1 clinical trial</keyword>
	<keyword>rare disease</keyword>
	<keyword>common underlie pathogenic mechanism</keyword>
	<keyword>neurological deficit</keyword>
	<keyword>gene mutation</keyword>
	<keyword>misfolded protein</keyword>
	<keyword>inadvertent error</keyword>
	<keyword>modulation gene</keyword>
	<keyword>master regulator peptide drug</keyword>
	<keyword>ALS relate gene</keyword>
	<keyword>mitochondrion dysfunction</keyword>
	<keyword>excitotoxicity</keyword>
	<keyword>axonal transport</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>protein aggregation</keyword>
	<keyword>pathogenesis</keyword>
	<keyword>target biomarkers</keyword>
	<keyword>efficacy biomarkers</keyword>
</DOC>